Myelogenous Leukemia Completed Phase 2 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0030998 (Myelogenous Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00133367Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusTreatment
NCT00144703Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationPrevention